ES2587381T3 - Uso de sapacitabina para tratar una enfermedad proliferativa - Google Patents

Uso de sapacitabina para tratar una enfermedad proliferativa Download PDF

Info

Publication number
ES2587381T3
ES2587381T3 ES08737080.5T ES08737080T ES2587381T3 ES 2587381 T3 ES2587381 T3 ES 2587381T3 ES 08737080 T ES08737080 T ES 08737080T ES 2587381 T3 ES2587381 T3 ES 2587381T3
Authority
ES
Spain
Prior art keywords
sapacitabine
treatment cycle
cndac
days
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08737080.5T
Other languages
English (en)
Spanish (es)
Inventor
Judy Chiao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclacel Ltd
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0708021A external-priority patent/GB0708021D0/en
Priority claimed from GB0723723A external-priority patent/GB0723723D0/en
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Application granted granted Critical
Publication of ES2587381T3 publication Critical patent/ES2587381T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES08737080.5T 2007-04-25 2008-04-24 Uso de sapacitabina para tratar una enfermedad proliferativa Active ES2587381T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0708021 2007-04-25
GB0708021A GB0708021D0 (en) 2007-04-25 2007-04-25 Use
GB0723723 2007-12-04
GB0723723A GB0723723D0 (en) 2007-12-04 2007-12-04 Use
PCT/GB2008/001424 WO2008132443A1 (en) 2007-04-25 2008-04-24 Use of sapacitabine to treat proliferative disease

Publications (1)

Publication Number Publication Date
ES2587381T3 true ES2587381T3 (es) 2016-10-24

Family

ID=39719125

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08737080.5T Active ES2587381T3 (es) 2007-04-25 2008-04-24 Uso de sapacitabina para tratar una enfermedad proliferativa

Country Status (6)

Country Link
US (2) US8536188B2 (cg-RX-API-DMAC7.html)
EP (1) EP2148676B1 (cg-RX-API-DMAC7.html)
JP (2) JP5852309B2 (cg-RX-API-DMAC7.html)
ES (1) ES2587381T3 (cg-RX-API-DMAC7.html)
PL (1) PL2148676T3 (cg-RX-API-DMAC7.html)
WO (1) WO2008132443A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
ES2587381T3 (es) 2007-04-25 2016-10-24 Cyclacel Limited Uso de sapacitabina para tratar una enfermedad proliferativa
EP2303283A2 (en) * 2008-05-15 2011-04-06 Katholieke Universiteit Leuven K.U. Leuven R&D Anti-cancer combination therapy
ES2743691T3 (es) 2011-04-14 2020-02-20 Cyclacel Ltd Régimen de dosis para sapacitabina y decitabina en combinación para tratar la leucemia mieloide aguda
US9872874B2 (en) 2012-05-15 2018-01-23 Cyclacel Limited Dosage regimen for sapacitabine and seliciclib
PT2941233T (pt) * 2013-01-07 2020-11-13 Univ Pennsylvania Composições e métodos para tratar linfoma cutâneo de células t
WO2021079129A1 (en) 2019-10-24 2021-04-29 Cyclacel Limited Dosing regimen
US11957701B2 (en) 2020-07-17 2024-04-16 Delta-Fly Pharma, Inc. Therapy and new therapeutic agent for blood cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60316775T2 (de) * 2002-03-08 2008-04-30 Novartis Ag Kombinationspräparat aus epothilone derivate und imidazotetrazinone
US20050014716A1 (en) * 2003-05-21 2005-01-20 Wang Jin Wei Pancreatic cancer treatment
EP1831200A2 (en) * 2004-12-21 2007-09-12 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents
PT1849470T (pt) * 2005-01-26 2017-09-22 Taiho Pharmaceutical Co Ltd Fármaco anticancro contendo alfa, alfa, alfa-trifluorotimidina e inibidor da timidina-fosforilase
US20090227674A1 (en) * 2005-08-18 2009-09-10 Richon Victoria M Combination methods fo saha and targretin for treating cancer
GB0526419D0 (en) * 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
GB0609530D0 (en) * 2006-05-12 2006-06-21 Cyclacel Ltd Combination
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
ES2587381T3 (es) 2007-04-25 2016-10-24 Cyclacel Limited Uso de sapacitabina para tratar una enfermedad proliferativa

Also Published As

Publication number Publication date
JP2010525042A (ja) 2010-07-22
PL2148676T3 (pl) 2016-12-30
JP5892565B2 (ja) 2016-03-23
JP5852309B2 (ja) 2016-02-03
US9675631B2 (en) 2017-06-13
US8536188B2 (en) 2013-09-17
US20140142058A1 (en) 2014-05-22
EP2148676B1 (en) 2016-05-25
JP2015013877A (ja) 2015-01-22
US20100125084A1 (en) 2010-05-20
WO2008132443A1 (en) 2008-11-06
EP2148676A1 (en) 2010-02-03

Similar Documents

Publication Publication Date Title
ES2587381T3 (es) Uso de sapacitabina para tratar una enfermedad proliferativa
ES2660263T5 (en) Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments
ES2893155T3 (es) Composición farmacéutica para inhibir el crecimiento de células madre de cáncer, que contiene un inhibidor de aldehído y un compuesto a base de biguanida
CN102459300A (zh) 用于治疗用途的新的7-脱氮嘌呤核苷
CN106074368A (zh) Pfkfb3抑制剂和用作抗癌治疗剂的方法
TWI641374B (zh) 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑
ES2746105T3 (es) Profármacos de 5-aza-pirimidina sililada útiles para tratar el cáncer
ES2672106T3 (es) Suspensiones de derivados de nucleósidos pirimidínicos cristalinos en cápsulas
US20250304612A1 (en) Therapeutic agent for blood cancer
CN101107001A (zh) 配合有α,α,α-三氟胸苷和胸苷磷酸化酶抑制剂的抗癌剂
US10080807B2 (en) Combination chemotherapy comprising a liposomal prodrug of mitomycin C
JP7032406B2 (ja) ダクチノマイシン組成物並びに骨髄異形成症候群及び急性骨髄性白血病の治療方法
JP2004517961A (ja) 癌治療法
US8124593B2 (en) Methods of treatment using sapacitabine
PT2754441E (pt) Composição para a prevenção e tratamento de cancro do pulmão de não pequenas células, contendo derivados de pirazino-triazina
ES2215307T3 (es) Composiciones con accion sinergica para combatir selectivamente tejidos tumorales.
CN104706656B (zh) 一种用于防治痴呆的天麻提取物或组合物
ES2393398T3 (es) Agente reforzante del efecto antitumoral, agente antitumoral y procedimiento de terapia para el cáncer
US11957701B2 (en) Therapy and new therapeutic agent for blood cancer
EP1541154A1 (en) Medicinal composition for drug-induced neuropathy
JP7447013B2 (ja) １，２－ナフトキノン誘導体化合物を含む固形癌または血液癌の予防または治療用薬学組成物
ES2299725T3 (es) Empleo de los derivados anfifilos del acido nucleosido fosfonoformico para el tratamiento de enfermedades infecciosas viricas.
RU2482855C2 (ru) Противоопухолевое средство, включающее производное цитидина и карбоплатин
CN104619325A (zh) 治疗肿瘤的组合药物及其应用
BR112019022459B1 (pt) Ácido nucleico modificado por oligonucleotídeo